FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4254771601> ?p ?o ?g. }

• W4254771601 endingPage "4" @default.
• W4254771601 startingPage "3" @default.
• W4254771601 abstract "The addition of ribavirin (RBV) to interferon-based therapy against hepatitis C virus (HCV) has been a therapeutic breakthrough. All therapies against HCV are based on a combination of pegylated interferon and RBV. The mechanism(s) of action of RBV remain partly unknown. The first attempts at triple drug therapies with protease inhibitors plus interferon showed that addition of RBV remains an essential element to achieve sustained virologic response (SVR). However, intake of RBV is associated with a severe dose-dependant haemolytic anaemia limiting the tolerance and the efficacy of treatment. Viramidin (VRD) is a prodrug of RBV and is metabolized primarily in the liver to RBV without accumulation of VRD in red blood cells thus reducing the degree of anaemia with an expected similar antiviral effect. In a phase III study described by Marcellin et al., a combination of VRD 600 mg bid plus Peginterferon alpha 2a was compared to a standard dosing regimen of RBV plus Peginterferon alpha 2a. Overall, SVR was higher in the RBV group (54%) vs. the VRD (40%) group and the non-inferiority point, a main objective of the study, was not reached. This trend of lower SVR in the VRD group was confirmed in genotypes 1 and 2/3 HCV patients. As expected, there was significantly less decrease in haemoglobin (54%) in the VRD group than in the RBV group (80%) p< 0.001. The lower efficacy of VRD in comparison to RBV still remains a debateable issue. The authors suggest that the optimal dosages of VRD still remains to be established; therefore, further studies are required to test the hypothesis that different dosages of VRD will provide a better safety profile with a similar efficacy as compared to RBV. The standard of care for HCV infected genotype 1 patients is the combination of Peginterferon recombinant alpha plus ribavirin for a duration of 48 weeks. There is a debate on the duration of therapy in those patients who achieve a rapid decline in viral load (>2 log drop at week 4) or a complete suppression of viral load (i.e. HCV RNA <50 IU/ml) at week 4. Some reports have suggested that in these patients a shorter treatment duration of 24 weeks would achieve a similar SVR with improved tolerance at a lower cost. However, higher relapse rates have also been reported in such patients. In a meta-analysis of 7 randomized controlled trials, Moreno et al., in this issue looked at the impact of shorter treatment duration on the SVR rate in HCV genotype 1 patients. Overall the SVR rate was lower in the short duration treatment groups due to a higher virologic relapse rate. In the subgroup of patients with RVR at week 4 and with a HCV RNA pre-treatment level below 400.000 IU/ml, the SVR rate was similar in both groups. Thus, the advantage of a shorter duration of therapy in genotype 1 patients seems limited to a small group of patients with rapid virological response and low viral load. Sorafenib has recently been licensed for treatment of unresectable hepatocellular carcinoma (HCC). Sorafenib targets Raf, Vascular endothelium growth factor receptor 1, 2, and 3 (VEGF-Rs) and platelet derived growth factor receptor (PDGF-Rβ). Sorafenib has been shown to improve survival in comparison to conventional treatment in patients with advanced unresectable HCC. The exact mode of action of Sorafenib is still unknown; however, its main action is believed to be through inhibition of VEGF-R. Despite the important therapeutic advance provided by Sorafenib, there is still a long way to go in control of HCC. Two studies in this issue of the Journal have explored the potential of enhanced activity of Sorafenib in combination therapy with other drugs. Chen et al. looked at the mechanism of the synergistic interactions between Sorafenib and bortezomib. Bortezomib is a proteasome inhibitor approved for the treatment of multiple myeloma. HCC cells in culture such as PLC-5 are highly resistant to bortezomib-induced apoptosis due to the inability of bortezomib to down regulate phospho-Akt in these cells. The investigators showed that pre-treatment with Sorafenib overcomes resistance to bortezomib in PLC-5 HCC cells and this effect is mediated through protein-phosphatase 2A (PP2A)-Akt inactivation. The Raf/MEK/ERK pathway is an important pathway in liver tumorigenesis. Huynh et al. showed that the inhibition of MEK/ERK pathway by AZD 6244 enhanced the antitumor effect of Sorafenib in a mice model of HCC. This paper suggests that a combination of angiogenesis inhibitors and the ERK/MEK pathway are effective to suppress tumour growth in a xenograft model of HCC by suppressing the feedback activation pathway of ERK/MEK. Thus, the anti-tumoral effect of the combination of Sorafenib/AZ 6244 was more effective than Sorafenib monotherapy in this model. In a third paper, Aihara et al. described the effect of AZD1152, an Aurora B kinase inhibitor on HCC growth. The Aurora kinase family of serine–threonine kinases controls chromosome assembly and segregation during mitosis. Aberrant expression of the Aurora kinases has been reported in several solid tumours. The effect of AZD1152 has been tested in human HCC cell lines and in a heterotopic and orthotopic xenograft mouse model. In these models, AZD1152 decreases tumour volume and improves survival of treated mice. Thus, the fundamental research in controlling HCC pathways is expected to open the field for new therapies against HCC; however, these experimental results require confirmation in human HCC patients." @default.
• W4254771601 created "2022-05-12" @default.
• W4254771601 creator A5059508363 @default.
• W4254771601 date "2010-01-01" @default.
• W4254771601 modified "2023-09-26" @default.
• W4254771601 title "Focus" @default.
• W4254771601 doi "https://doi.org/10.1016/j.jhep.2009.10.017" @default.
• W4254771601 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19923033" @default.
• W4254771601 hasPublicationYear "2010" @default.
• W4254771601 type Work @default.
• W4254771601 citedByCount "0" @default.
• W4254771601 crossrefType "journal-article" @default.
• W4254771601 hasAuthorship W4254771601A5059508363 @default.
• W4254771601 hasBestOaLocation W42547716011 @default.
• W4254771601 hasConcept C127413603 @default.
• W4254771601 hasConcept C142462285 @default.
• W4254771601 hasConcept C159047783 @default.
• W4254771601 hasConcept C188198153 @default.
• W4254771601 hasConcept C2522874641 @default.
• W4254771601 hasConcept C2776178377 @default.
• W4254771601 hasConcept C2776408679 @default.
• W4254771601 hasConcept C2776455275 @default.
• W4254771601 hasConcept C2776461080 @default.
• W4254771601 hasConcept C2780040827 @default.
• W4254771601 hasConcept C2781143361 @default.
• W4254771601 hasConcept C2909179924 @default.
• W4254771601 hasConcept C2993143319 @default.
• W4254771601 hasConcept C71924100 @default.
• W4254771601 hasConcept C78519656 @default.
• W4254771601 hasConcept C98274493 @default.
• W4254771601 hasConceptScore W4254771601C127413603 @default.
• W4254771601 hasConceptScore W4254771601C142462285 @default.
• W4254771601 hasConceptScore W4254771601C159047783 @default.
• W4254771601 hasConceptScore W4254771601C188198153 @default.
• W4254771601 hasConceptScore W4254771601C2522874641 @default.
• W4254771601 hasConceptScore W4254771601C2776178377 @default.
• W4254771601 hasConceptScore W4254771601C2776408679 @default.
• W4254771601 hasConceptScore W4254771601C2776455275 @default.
• W4254771601 hasConceptScore W4254771601C2776461080 @default.
• W4254771601 hasConceptScore W4254771601C2780040827 @default.
• W4254771601 hasConceptScore W4254771601C2781143361 @default.
• W4254771601 hasConceptScore W4254771601C2909179924 @default.
• W4254771601 hasConceptScore W4254771601C2993143319 @default.
• W4254771601 hasConceptScore W4254771601C71924100 @default.
• W4254771601 hasConceptScore W4254771601C78519656 @default.
• W4254771601 hasConceptScore W4254771601C98274493 @default.
• W4254771601 hasIssue "1" @default.
• W4254771601 hasLocation W42547716011 @default.
• W4254771601 hasLocation W42547716012 @default.
• W4254771601 hasOpenAccess W4254771601 @default.
• W4254771601 hasPrimaryLocation W42547716011 @default.
• W4254771601 hasRelatedWork W118298973 @default.
• W4254771601 hasRelatedWork W1911438026 @default.
• W4254771601 hasRelatedWork W2007857109 @default.
• W4254771601 hasRelatedWork W2023309777 @default.
• W4254771601 hasRelatedWork W2031380552 @default.
• W4254771601 hasRelatedWork W2036281098 @default.
• W4254771601 hasRelatedWork W2159449285 @default.
• W4254771601 hasRelatedWork W2320534176 @default.
• W4254771601 hasRelatedWork W2420998368 @default.
• W4254771601 hasRelatedWork W4240982748 @default.
• W4254771601 hasVolume "52" @default.
• W4254771601 isParatext "false" @default.
• W4254771601 isRetracted "false" @default.
• W4254771601 workType "article" @default.